Ineurous IP

No one storms into a startup’s office and steals its ideas. There’s no dramatic attack, no visible threat. Instead, the damage happens quietly through missed filings, unsigned agreements, and assumptions that protection can wait. By the time founders realize what’s gone wrong, the consequences are often irreversible. Startups don’t fail because someone attacked them they fail because they didn’t protect what they built.

In a rapidly evolving world driven by innovation, intellectual property plays a critical role in shaping industries. Patents, in particular, are designed to reward inventors, protect technological advancements, and encourage further research. But what happens when patents meant to enable innovation start to block it instead? To understand this, let’s step away from legal jargon for a moment and imagine a simple, real-world scenario.

The recent expiry of patent protection for semaglutide in India has triggered a significant shift in the pharmaceutical market, offering a clear illustration of how the Indian patent system operates in practice. Originally developed by Novo Nordisk, semaglutide is the active ingredient behind widely recognized drugs such as Ozempic and Wegovy. With the lapse of patent protection, the Indian market witnessed a rapid and large-scale entry of generic manufacturers.